| scholarly article | Q13442814 |
| P2093 | author name string | Peter D Friedmann | |
| Harold A Pollack | |||
| Christina M Andrews | |||
| Thomas A D'Aunno | |||
| P2860 | cites work | Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption | Q37352521 |
| The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone | Q40008111 | ||
| Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability | Q40358105 | ||
| Medicine. The NIH Roadmap | Q40558359 | ||
| Factors determining how early adopter physicians use buprenorphine in treatment | Q42730437 | ||
| Optimizing opioid detoxification: rearranging deck chairs on the Titanic | Q44335481 | ||
| Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication | Q44875497 | ||
| HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. | Q45901297 | ||
| Changes in methadone treatment practices: results from a national panel study, 1988-2000. | Q46269532 | ||
| Changes in Methadone Treatment Practices: Results from a Panel Study, 1988–1995 | Q58280435 | ||
| Variations in methadone treatment practices. Results from a national study | Q67717631 | ||
| A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice | Q81245499 | ||
| Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence | Q24243180 | ||
| The meaning of translational research and why it matters | Q28264016 | ||
| Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science | Q29620036 | ||
| Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors | Q31041707 | ||
| Facilitating Factors and Barriers to the Use of Medications in Publicly Funded Addiction Treatment Organizations | Q34111054 | ||
| Adoption and implementation of medications in addiction treatment programs | Q34607338 | ||
| Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation | Q34925449 | ||
| Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure | Q35042742 | ||
| Pharmacologic treatments for opioid dependence: detoxification and maintenance options | Q35454866 | ||
| Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders | Q36192673 | ||
| Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. | Q36627877 | ||
| State policy influence on the early diffusion of buprenorphine in community treatment programs | Q36766544 | ||
| The adoption of innovations by provider organizations in health care | Q36824393 | ||
| Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs | Q36928546 | ||
| Dosage patterns in methadone treatment: results from a national survey, 1988-2005. | Q37037332 | ||
| Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. | Q37352259 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 43-60 | |
| P577 | publication date | 2013-09-18 | |
| P1433 | published in | Medical Care Research and Review | Q6806278 |
| P1476 | title | Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs | |
| P478 | volume | 71 |
| Q38621655 | A mixed methods study of HIV-related services in buprenorphine treatment |
| Q89187257 | A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees |
| Q47182845 | At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care". |
| Q60480946 | Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers |
| Q38828787 | Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System |
| Q36290564 | Correlates of Motivational Interviewing Use Among Substance Use Treatment Programs Serving American Indians/Alaska Natives |
| Q89997366 | Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics |
| Q36446470 | Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform |
| Q44351053 | Economic Conditions and Drug and Opioid Overdose Deaths |
| Q39062397 | Estimating State Transitions for Opioid Use Disorders |
| Q35400440 | Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. |
| Q41210999 | Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders |
| Q36798074 | Lessons From Medicaid's Divergent Paths On Mental Health And Addiction Services |
| Q47412301 | Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio |
| Q36278101 | Quality of life as an outcome of opioid use disorder treatment: A systematic review. |
| Q36090286 | Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States |
| Q46830109 | State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. |
| Q64070116 | Strengthening partnerships between substance use researchers and policy makers to take advantage of a window of opportunity |
| Q39095973 | The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California |
| Q36757250 | Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities |
| Q35795201 | Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. |
Search more.